The market for immuno-oncology medications in India was valued at US$ 172.8 million in 2018 and is predicted to grow at a CAGR of 13.1 percent from 2018 to 2026.

                                                 

Biological therapeutic goods include immuno-oncology products. Lung cancer, breast cancer, colon cancer, and cervical cancer are among the cancers for which immuno-oncology medicines are commonly employed in therapeutic applications. The major players in the Indian immuno-oncology medicines market are concentrating on new technology and product development. Several biopharmaceutical companies and research institutions have been developing biologics for cancer treatment on their own. For example, researchers at IIT Bombay's Tata Centre for Technology and Design are focusing on producing an indigenous CAR (chimeric antigen receptor) T-cell therapy that is accessible to Indian cancer patients.

The Indian Immune-Oncology Drugs Market is predicted to grow due to rising cancer cases and the introduction of novel immuno-oncology therapies.

During the forecast period, rising cancer occurrences in India are expected to increase the India Immune-Oncology Drugs Market. Breast cancer incidence was 25.8 per 100,000 women in 2018 and is anticipated to reach 35 per 100,000 women in 2026, according to the Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR).

Restraints in the Indian Immuno-Oncology Drugs Market

Inadequate distribution of inexpensive and equitable cancer treatment pharmaceuticals in India is a major restraining issue for the Indian immune-oncology drugs market, which hampers the India immune-oncology drugs industry. For example, according to data published in the Lancet Journal in 2014, India's public spending on cancer remains below US$ 10 per person (compared to around US$ 100 per person in high-income or developed countries), while overall public spending on healthcare remains only slightly above 1% of GDP.

India Immune-Oncology Drugs Market - Competitive Landscape

Key players operating in the India Immune-Oncology Drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.